The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.
The conversation is about considering switching from Fluridil to Pyrilutamide for hair loss treatment. Pyrilutamide is suggested to be more effective, with a recommendation to use the 1% variant twice daily.
Researching the cause of hair loss and treating it by preventing DHT in the scalp with medication such as finasteride or dutasteride, estrogen, minoxidil, dermarolling, and possible topical antiandrogens.
A user's success in hair regrowth after taking oral and topical medications, such as minoxidil and dutasteride, and using microneedling. Other users shared their experiences and advice with treatments used to reverse hair loss.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
The user reports taking high dosage oral minoxidil (10mg/day) for hair growth, which causes facial bloating. They tried using the diuretic furosemide to reduce bloating, but it was ineffective.
The user maintained hair with minoxidil, alfatradiol, and fluridil after stopping finasteride due to erectile dysfunction. They recently added pyrilutamide and are seeking feedback on its effectiveness after six months of use.
The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.
A 30-year-old is seeking advice on hair loss treatment, currently using oral minoxidil, finasteride, mesotherapy, and a supplement. They are experiencing shedding and are anxious about the effectiveness of the treatment, asking if they should continue or consider other options like topicals or microneedling.
Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.
A satirical discussion about a 2-year-old cat experiencing hair thinning, humorously suggesting treatments like minoxidil and finasteride. Users joke about the effectiveness and risks of these treatments.
Eucapill 2% used for 1 month reduced shedding from 200 to 10/20 hairs daily with no side effects. Finasteride caused side effects like ED and watery semen.
The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.
The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.
A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.
The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
Using a microdose of finasteride on the scalp with minoxidil as a carrier may have positive effects with minimal side effects. The user is also considering the effects of sulforaphane or broccoli sprouts on hair loss.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
Tretinoin may help more minoxidil convert to its active form and could potentially increase its absorption, raising concerns about safety if too much enters the bloodstream. It's unclear if tretinoin affects finasteride absorption.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
A new painless microneedle patch shows promise in reversing hair loss. The discussion focuses on potential new treatments beyond common options like Minoxidil, finasteride, and RU58841.
Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.
Minoxidilmax offering a 0.5% Pyrilutamide solution and debating the cost, effectiveness, and safety of using it alone or with other treatments such as Finasteride and Minoxidil.
Hair mesotherapy with dutasteride is popular in Europe and can be effective, especially when combined with oral dutasteride. Some users suggest using topical dutasteride with microneedling as an alternative, though it may be painful.
Topical dutasteride with microneedling is effective for androgenetic alopecia, improving hair thickness and density. Further research is needed to confirm long-term efficacy.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.
Combining finasteride with minoxidil and tretinoin is discussed, with concerns about potential overdose. It is suggested that high doses of finasteride do not provide additional benefits beyond 1 mg.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.